ALL Video Channel
Explore the latest insights and summaries from experts in ALL.
Therapeutic Agents
Insights from 2024 EHA Annual Meeting
Responder Analysis From the PhALLCON Trial: Ponatinib vs. Imatinib in Newly Diagnosed Ph+ ALL
FEATURING
Jose-Maria Ribera
- 107 views
- June 24, 2024
- 1
SOHO Brazil 2024
How Are Targeted Therapies Redefining the Treatment Paradigm in ALL in Adults
FEATURING
Jan Burger
- 124 views
- July 11, 2024
- 1
Amgen Sponsorship
New Approval for Frontline Consolidation in Patients with CD19-positive Ph(–) B-cell precursor ALL
FEATURING
James Mccloskey
- 716 views
- August 20, 2024
- 3
University of Colorado Cancer Center
Frontline Treatment of ALL: Current Standards and Emergence of CAR-T
FEATURING
Marc Schwartz
- 69 views
- August 1, 2024
Sarah Tasian
Recent Updates on Blinatumomab in ALL: FDA Approval in 1L and Incorporation Into Practice
- 509 views
- August 9, 2024
- 5
Robert Zeiser
CSF1R's Role in Modulating Inflammation and Fibrosis in cGVHD
- 57 views
- August 13, 2024
- 1
Salman Fazal
Blinatumomab in First-Line ALL - Safety, Efficacy, and Experience
- 203 views
- August 27, 2024
- 3
MyCancerHaven
Incorporating Blinatumomab and Inotuzumab Into 1L ALL Treatment
FEATURING
Ravi Vij,
Nicholas Short
- 167 views
- August 30, 2024
- 2
UChicago Medicine Annual Practice Updates in Hematology and Oncology
UChicago Medicine Best of ASCO® 2024: CML, AML, ALL
FEATURING
Mariam Nawas
- 45 views
- September 3, 2024
XV Eurasian Hematology-Oncology Congress - EHOC 2024
Debates in Ph+ ALL: Allo-SCT Is Not Necessary Upfront in Adult Patients
FEATURING
Elias Jabbour
- 44 views
- September 6, 2024
Daniel Wolff
The Role of Axatilimab in Targeting CSF1R for Inflammation and Fibrosis in cGVHD – Recently FDA Approved
- 137 views
- September 6, 2024
- 1
Talha Badar
Updates in ALL: Incorporating Immunotherapy in Frontline Management
- 275 views
- September 16, 2024
- 3
University of Colorado Department of Medicine
Cellular Therapy in 2024: What, Why, When, Who… and Where Are We Going?
FEATURING
Jonathan Gutman
- 302 views
- September 19, 2024
- 2
XV Eurasian Hematology-Oncology Congress - EHOC 2024
Immunotherapy and Sequencing CD19-Targeted Therapies in Adults With R/R ALL
FEATURING
Elias Jabbour
- 44 views
- September 27, 2024
- 1
Brittany Ragon
Targeting cGVHD: Mechanism of Action of Axatilimab Compared to Other Available Agents
- 24 views
- October 14, 2024
Marlise R. Luskin
Treating Adult B-ALL: CAR-T vs. Bispecifics vs. Monoclonals
- 103 views
- October 21, 2024
- 2
Marina Konopleva
Considering Venetoclax in AML and ALL - Which Patients and Why
- 58 views
- October 23, 2024
- 2
Noah Merin
Axatilimab in cGVHD: Mechanism of Action and Comparison With Current Therapeutic Agents
- 88 views
- November 10, 2024
Indy Hematology Review
State of the Art in 2024: Emerging Therapies in Hematologic Malignancies
FEATURING
Ruemu Birhiray
- 925 views
- April 16, 2024
- 5
Fred Hutchinson Cancer Center
Blinatumomab for Ph- ALL in First MRD-Negative Remission: E1910 and Beyond
FEATURING
Ryan Cassaday
- 451 views
- April 29, 2024
- 4
Yale Cancer Center
Summary of Promising Recent Studies in LR-MDS, HR-MDS, and R/R AML
FEATURING
Rory Shallis
- 93 views
- May 16, 2024
Rush University Medical Center
Cellular Therapy Strategies for Persistent Disease After Induction for B-ALL
FEATURING
Vinod Pullarkat
- 57 views
- May 29, 2024
Rush University Medical Center
[duplicate] Is Post-HSCT Maintenance the SOC for AML?
FEATURING
Mark Levis
- May 29, 2024
Elias Jabbour
CRS and ICANS With BiTEs in ALL - How to Manage With Dose Adjustments
- 227 views
- April 10, 2024
Stanford Medicine
Risk of Second Malignancies and T-Cell Lymphoma After CAR T-Cell Therapy
FEATURING
Mark Hamilton
- 201 views
- June 28, 2024
- 3
Winship Cancer Institute - Emory University
FDA Approved First Oral Solution of Imatinib
FEATURING
Aseala Abousaud
- 14 views
- December 13, 2024
2024 ASH Annual Meeting Insights Hub
ASH 2024 Insights: COG AALL1731 - Blinatumomab Added to Chemo in Newly Diagnosed NCI Standard Risk Pediatric B-ALL
FEATURING
Sumit Gupta
- 119 views
- December 19, 2024
- 1